伊人直播

Table 1: unaudited sales reports 鈥� measured sales

Aggregate net sales subject to the affordability mechanism (measured sales):

Year	2019 voluntary scheme	Statutory scheme	Parallel imports	Total
2018	拢8,847尘	拢1,650尘	拢771尘	拢11,268尘
2019	拢9,093尘	拢1,668尘	拢697尘	拢11,458尘
2020 Q1	拢2,755尘	拢99尘	拢191尘	拢3,045尘
2020 Q2	拢2,402尘	拢95尘	拢176尘	拢2,673尘
2020 Q3	拢2,614尘	拢87尘	拢199尘	拢2,899尘
2020 Q4	拢2,887尘	拢98尘	拢200尘	拢3,186尘
2020	拢10,649尘	拢379尘	拢766尘	拢11,794尘
2021 Q1	拢2,684尘	拢93尘	拢177尘	拢2,955尘
2021 Q2	拢2,816尘	拢100尘	拢197尘	拢3,114尘
2021 Q3	拢3,072尘	拢103尘	拢204尘	拢3,379尘
2021 Q4	拢3,221尘	拢104尘	拢226尘	拢3,551尘
2021	拢11,794尘	拢399尘	拢805尘	拢12,998尘

Table 1 notes

1. Table 1 sets out aggregate information about measured sales subject to the affordability mechanism. It includes information received on parallel imports, and information from audited annual sales reports and unaudited quarterly sales reports provided by members of the 2019 voluntary scheme and the statutory scheme.
2. The baseline for measured sales in respect of the statutory scheme and parallel imports has been calculated in accordance with annex 4, paragraph 1 of the 2019 voluntary scheme.
3. 鈥楳easured sales鈥� is defined in the glossary of the 2019 voluntary scheme for branded medicines pricing and access as 鈥渟ales of scheme products by scheme members, statutory scheme sales and parallel import sales, but excluding exemptions from measured sales鈥�.
4. Figures for the 2019 voluntary scheme reflect any audited sales reports received. Annual totals from 2019 onwards for the statutory scheme reflect any audited sales reports received. The 2021 annual total is the sum of the 2021 quarters rather than a specific annual return.

Measured sales in any particular period reflect all relevant scheme members in either the 2019 voluntary scheme or statutory scheme during that period. For example, several companies moved from the statutory scheme to the voluntary scheme at the start of 2020. Those companies鈥� measured sales will appear under the statutory scheme in 2019 but the voluntary scheme in 2020.

Table 2: 2019 voluntary scheme sales reports 鈥� eligible sales and resulting total scheme payments

Period	Aggregate eligible sales (column 1)	Resulting aggregate scheme payments (column 2)
2019	拢8,797尘	拢845尘
2020	拢10,065尘	拢594尘
2021 Q1	拢2,450尘	拢125尘
2021 Q2	拢2,636尘	拢134尘
2021 Q3	拢2,906尘	拢148尘
2021 Q4	拢3,058尘	拢156尘
2021	拢11,050尘	拢564尘

Table 2 notes

Table 2, which is derived from unaudited quarterly sales reports and any audited annual sales reports received from members of the 2019 voluntary scheme, sets out aggregate information showing eligible sales covered by the scheme payment and the resulting scheme payments. The 2021 annual total is the sum of the 2021 quarters rather than a specific annual return.

There are 2 columns of information:

• column 1: aggregate eligible sales
• column 2: resulting aggregate scheme payments due for the respective periods

Note: eligible sales is defined in the glossary of the 2019 voluntary scheme as 鈥渟ales of scheme products but excluding exemptions from eligible sales鈥�. The percentage payment applies to these sales. Eligible sales excludes certain types of sales, including the first 拢5 million of sales by a medium-sized company and new active substance (NAS) sales. Both of these sales categories are, however, included in measured sales and, therefore, the calculation of the overall sum to be repaid across all scheme members.

Table 3: statutory scheme sales reports 鈥� net sales covered by the statutory scheme payment and resulting payments

Statutory scheme payment and resulting payments	2019	2020
Aggregate net sales covered by the applicable annual statutory scheme payment (a)	拢635尘	拢34尘
Resulting aggregate statutory scheme payment (b)	拢63尘	拢2尘
Net sales of extant frameworks and public contracts subject to 7.8% payment (c)	拢311尘	拢17尘
Resulting statutory scheme 7.8% payment (d)	拢24尘	拢1尘
Total resulting statutory scheme payment (b + d)	拢87尘	拢4尘

Statutory scheme payment and resulting payments	Jan to Mar 2021	Apr to Jun 2021	Jul to Sep 2021	Oct to Dec 2021
Aggregate net sales covered by the applicable annual statutory scheme payment (a)	拢8尘	拢17尘	拢86尘	拢86尘
Resulting aggregate statutory scheme payment (b)	拢1尘	拢2尘	拢9尘	拢9尘
Net sales of extant frameworks and public contracts subject to 7.8% payment (c)	拢4尘	拢4尘	拢5尘	拢4尘
Resulting statutory scheme 7.8% payment (d)	<拢1尘	<拢1尘	<拢1尘	<拢1尘
Total resulting statutory scheme payment (b + d)	拢1尘	拢2尘	拢10尘	拢10尘

Table 3 notes

Table 3 is derived from audited and unaudited statutory scheme sales reports. It sets out aggregate unaudited quarterly information showing net sales covered by the statutory scheme payment and the resulting payments.

Table 4: 2019 voluntary scheme updated calculations 鈥� measured sales growth rates and projected 2023 payment percentage

Observed and adjusted forecast modelled measured sales growth rates:

	2019 observed	2020 observed	2021 observed	2022 forecast	2023 forecast
2019 voluntary scheme	2.78%	16.04%	9.95%	5.88%	5.63%
Statutory scheme	1.09%	-77.29%	5.36%	5.78%	5.47%
Parallel import	-9.56%	9.87%	5.06%	0.93%	-0.42%
Overall	1.69%	2.08%	9.48%	5.56%	5.26%

Confirmed and projected 2019 voluntary scheme payment percentages:

	2019 confirmed	2020 confirmed	2021 confirmed	2022 confirmed	2023 projected
2019 voluntary scheme	9.6%	5.9%	5.1%	15.0%	23.7%

Table 4 notes

1. The 2022 payment percentage was set at 15% following an agreement between the Department of Health and Social Care and the Association of the British Pharmaceutical Industry.^{[footnote 1]}
2. Table 4 shows the observed full year growth from 2019 to 2021, as well as the adjusted forecast growth for 2022 and 2023 based on the latest data.
3. In accordance with annex 4, paragraph 34 of the scheme documentation, companies whose sales exceed (or fall below) 拢5尘 between years, and so are included/excluded from measured sales of subsequent years, are excluded from the growth calculations.

Table 4 also shows the resulting projected payment percentage for 2023 based on the latest data up to the end of Q4 2021. The actual 2023 payment percentage will be based on, in addition to other elements, the observed full year measured sales growth from 2019 to 2021, proxy 2022 growth (observed year-to-date growth to Q3 2022) and adjusted forecast growth in 2023. The projected payment percentage for 2023 is calculated using scheme mechanics based on current sales growth adjusted forecasts in 2022 and 2023, and a 15% payment percentage in 2022. This projection is not a forecast or prediction and will be updated as we get more data with the final 2023 payment percentage set in December, based on data up to the end of Q3 2022.

General notes

Note 1: the information in all tables is that held on the Department of Health and Social Care鈥檚 database at 16 February 2022.

Note 2: totals may not sum due to rounding.

Note 3: all tables are subject to future correction, such as where audited data replaces best available data, and will be updated at each quarterly publication point to reflect the latest available information. The audit and reconciliation arrangements are set out in paragraphs 4.26 to 4.31 of the 2019 voluntary scheme. The statutory scheme audit requirements are set out at paragraph 23 of the .